The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Partly supported · 6 No basis given · 4 Couldn’t confirm · 3 Own method · 1 Supported · 1 Sources not found · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 9,066
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
Background
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 798
ICU Management of the Patient With Fibrotic Interstitial Lung Disease
Krishnan, A., Janz, D. R., & Lammi, M. R. (2023) · CHEST Critical Care · doi:10.1016/j.chstcc.2023.100020 · Cited by 13
Monitoring practices of chronic lung allograft dysfunction in pediatric lung transplantation
Avdimiretz, N., Radtke, T., & Benden, C. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.26187 · Cited by 13
Lo, W., Hiramoto, B. A., Goldberg, H. J., Sharma, N., & Chan, W. W. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i21.3292 · Cited by 12
Assessment and Management of Cough in Idiopathic Pulmonary Fibrosis: A Narrative Review
Liu, S., & Ye, X. (2023) · Lung · doi:10.1007/s00408-023-00653-3 · Cited by 12
“Currently, lung transplantation is the only curative treat-ment for IPF, effectively improving cough and extending patient survival [84].”
BackgroundThe ageing of people living with cystic fibrosis: what to expect now?
Montiel, A. F., Fernández, A. Á., Amigo, M. C., Traversi, L., Clofent, D., Loor, K., & Polverino, E. (2024) · European Respiratory Review · doi:10.1183/16000617.0071-2024 · Cited by 15
Recurrence of primary disease following lung transplantation
Esendagli, D. R., Ntiamoah, P., Küpeli̇, E., Bhardwaj, A., Ghosh, S., Mukhopadhyay, S., & Mehta, A. C. (2022) · ERJ Open Research · doi:10.1183/23120541.00038-2022 · Cited by 14
“Patients with pulmonary vascular diseases that are associated with pulmonary hypertension (PH) without a response to targeted medical therapy are also candidates for LTx [2].”
BackgroundInfluentialIndications for pediatric lung transplantation in 2025: A new era
Avdimiretz, N., Hayes, D., Solomon, M. P., et al. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100323 · Cited by 11
Self-citationPflaum, M., Jurmann, S., Katsirntaki, K., et al. (2021) · Membranes · doi:10.3390/membranes12010035 · Cited by 11
“However, due to the limited number of organ donors and strict requirements to consider lungs as transplantable, only a few and rigorously selected patients can be transplanted [1].”
BackgroundMalnutrition in solid organ transplant patients: A review of the literature
Lorden, H. M., Engelken, J., Sprang, K., Rolfson, M., Mandelbrot, D. A., & Parajuli, S. (2023) · Clinical Transplantation · doi:10.1111/ctr.15138 · Cited by 11
Clinical features of pulmonary arterial hypertension associated with systemic sclerosis
Tuhy, T., & Hassoun, P. M. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264906 · Cited by 11
Advances in lung transplantation: 60 years on
Paraskeva, M. A., & Snell, G. I. (2024) · Respirology · doi:10.1111/resp.14721 · Cited by 11
“Extremes of BMI are associated with increased mortality after LTx. 9,10 In a recent US study, compared to a BMI of 24 kg/m 2 , a LTx recipient with a BMI 16 kg/m 2 had a 38% increase in mortality-related particularly to acute respiratory failure, CLAD and infection.”
BackgroundClermidy, H., Mercier, O. M., Brioude, G., Mordant, P., Fadel, G., Picard, C., Chatron, E., Pavec, J. L., Roux, A., Reynaud‐Gaubert, M., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.06.009 · Cited by 11
Patient-centered care in pulmonary fibrosis: access, anticipate, and act
Hofman, D. E., Magrì, T., Moor, C. C., Richeldi, L., Wijsenbeek, M. S., & Waseda, Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02997-7 · Cited by 14
“Furthermore, early referral for LTx evaluation is recommended given the significant impact of ILD-asso-ciated PH [86].”
BackgroundInfluentialSelf-citationOutcomes after lung transplantation in recipients aged 70 years or older
Olson, M. T., Elnahas, S., Roy, S. B., Razia, D., Kang, P. T., Bremner, R. M., Smith, M. A., Arjuna, A., & Walia, R. (2021) · Clinical Transplantation · doi:10.1111/ctr.14505 · Cited by 12
Low body mass index as a barrier to lung transplant in cystic fibrosis
Jennerich, A. L., Pryor, J. B., Wai, T. Y. H., Kapnadak, S. G., Aitken, M. L., Goss, C. H., & Ramos, K. J. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.12.001 · Cited by 11
Self-citationKoons, B., Anderson, M. R., Smith, P. J., Greenland, J. R., & Singer, J. P. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00365-2 · Cited by 11
“Increased transplant rates for older adults are driven by the aging population worldwide [9], changes in lung allocation systems that prioritize idiopathic pulmonary fibrosis (IPF), the incidence and prevalence of which increases with age [10], and growing willingness on behalf of transplant centers to list and transp…”
BackgroundSelf-citationCannabinoids and solid organ transplantation: Psychiatric perspectives and recommendations
Winder, G. S., Andrews, S. R., Banerjee, A. G., Hussain, F., Ivkovic, A., Kuntz, K. K., Omary, L., Shenoy, A., Thant, T., VandenBerg, A., et al. (2022) · Transplantation Reviews · doi:10.1016/j.trre.2022.100715 · Cited by 11
Current and future role of double-lung transplantation for bilateral lung cancer
Lee, J., Schellenberg, S., Chung, L. I., Bharat, A., & Chae, Y. K. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100772 · Cited by 11
“Lung transplantation should be reserved for lung-limited AIS, MIA, lepidic predominant adenocarcinoma, or unresectable diffuse cancer that is refractory to oncologic treatments [37,40].”
BackgroundEpidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review
Montero, I. E., Hernández‐González, F., & Sellarés, J. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00302-5 · Cited by 11
The Lung Transplant Candidate, Indications, Timing, and Selection Criteria
Mannem, H. C., Aversa, M. M., Keller, T., & Kapnadak, S. G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.001 · Cited by 10
Self-citationOpportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial
Magda, G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.012 · Cited by 10
Bronchopulmonary dysplasia in adults: Exploring pathogenesis and phenotype
Wozniak, P. S., Makhoul, L., & Botros, M. M. (2023) · Pediatric Pulmonology · doi:10.1002/ppul.26795 · Cited by 10
Lung transplantation in HIV seropositive recipients: An analysis of the UNOS registry
Donohue, J. K., Chan, E. G., Clifford, S., Ryan, J. P., Furukawa, M., Haidar, G., Bertani, A., Hage, C. A., & Sánchez, P. G. (2024) · Clinical Transplantation · doi:10.1111/ctr.15246 · Cited by 13
O’Donnell, J. E. M., Hastings, L. A., BRIODY, J. N., Chan, C. L., Colombo, C., Douglas, T. A., Freedman, S. D., Gonska, T. Y., Greenfield, J. R., Leung, D. H., et al. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26970 · Cited by 12
“129 Noncompliance is also a relative contra-indication, and possibly secondary to this, adolescents with CF have worse outcomes than those without.”
BackgroundPena, T. A., Wright, B. A., Parekh, K. R., & Klesney‐Tait, J. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100171 · Cited by 11
Kolaitis, N. A., Barnes, H., Levine, D. J., Castillo, H., Arcasoy, S. M., Bacchetta, M. D., Benvenuto, L. J., Rosenzweig, E. B., Cevasco, M., Demarest, C. T., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70088 · Cited by 12
Self-citationReed, A. K., Mercier, O. M., Behr, J., Dave, K., Dellgren, G., Kotecha, S., Kukreja, J., Landry, C., Levvey, B. J., Lyster, H. S., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.07.033 · Cited by 15
Self-citationO’Carroll, M. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758731 · Cited by 10
Extracorporeal life support as a bridge to lung transplantation: a narrative review
Faccioli, E., & İnci, İ. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1163 · Cited by 11
DAVIDSON, S., Idris, M. Y., Awad, C., King, M. H., Westney, G. E., Ponce, M., Rodriguez, A., Lipsey, K. L., Flenaugh, E. L., & Foreman, M. G. (2024) · International Journal of COPD · doi:10.2147/copd.s430249 · Cited by 11
Indications for Lung Transplantation and Patient Selection
Son, J., & Shin, C. (2022) · Journal of Chest Surgery · doi:10.5090/jcs.22.057 · Cited by 10
“Despite these limitations, the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence…”
BackgroundInfluentialCritical Care Management Following Lung Transplantation
Jeon, K. (2022) · The Korean Journal of Thoracic and Cardiovascular Surgery · doi:10.5090/jcs.22.067 · Cited by 11
“Lung transplantation for patients with various end-stage lung diseases has become an increasingly standard therapy [1].”
BackgroundSyed, M. K. H., Bruck, O., Kumar, A., & Surani, S. (2023) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v12.i3.153 · Cited by 9
Westall, G. P., Barnes, H., Levin, K., Gaffney, N., Harris, J., Martinez, O., Emsley, C., Fuller, L., Levvey, B. J., Snell, G. I., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.11.009 · Cited by 11
Hollebeke, M. V., Chohan, K., Adams, C. J., Fisher, J. H., Shapera, S., Fidler, L. M., Goligher, E. C., Martinu, T., Wickerson, L. M., Mathur, S., et al. (2024) · Chronic Respiratory Disease · doi:10.1177/14799731241240786 · Cited by 10
“34 Moreover, admission and follow-up at a lung-transplant center, along with younger age and higher socioeconomic status have been shown to be associated with lung transplantation in IPF.”
BackgroundBarnes, H., Corte, T. J., Keir, G. J., Khor, Y. H., Limaye, S., Wrobel, J. P., Veitch, E. M., Harrington, J., Dowman, L., Beckert, L., et al. (2024) · Respirology · doi:10.1111/resp.14847 · Cited by 13
“176 While there is no absolute upper age limit, increased recipient age is a risk factor for both 12-month and conditional 5-year survival post lung transplantation.”
Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons
Giulianelli, G., Cocconcelli, E., Fiorentù, G., Bernardinello, N., Balestro, E., & Spagnolo, P. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00296-0 · Cited by 12
“Age > 65 should be considered a relative contraindication (ISHLT guidelines) [30].”
Ramos, K. J., Wai, T. H., Sykes, J. R., Ma, X., Stephenson, A. L., Jennerich, A. L., Kapnadak, S. G., Mayer-Hamblett, N., & Goss, C. H. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.08.008 · Cited by 9
Self-citationGauvreau, A., Carrier, F. M., Poirier, C. D., Morisset, J., Lands, L. C., Lavoie, A., Nasir, B., Ferraro, P., & Luong, M. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.02.001 · Cited by 9
Lung Transplantation for People Living With HIV: Promising Mid-term Outcomes
Ralphs, A. S., Anderson, S. T., Langlais, B., D’Cunha, J., & dos Santos, P. R. (2023) · Transplantation · doi:10.1097/tp.0000000000004861 · Cited by 9
“14,15 According to our analysis of OPTN data, 59 patients who are HIV-positive by either serostatus or NAT testing have undergone LTx since 2004.”
MethodCystic fibrosis in children: A pediatric anesthesiologist’s perspective
Williamson, D. M., & Sharma, A. (2021) · Pediatric Anesthesia · doi:10.1111/pan.14384 · Cited by 9
Hartzler, A. L., Bartlett, L., Hobler, M. R., Reid, N., Pryor, J. B., Kapnadak, S. G., Berry, D. L., Lober, W. B., Goss, C. H., Ramos, K. J., et al. (2022) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocac176 · Cited by 10
Self-citationMolecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis
Cocconcelli, E., Bernardinello, N., Castelli, G., Petrarulo, S., Bellani, S., Saetta, M. P., Spagnolo, P., & Balestro, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310767 · Cited by 9
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., et al. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231165912 · Cited by 8
van Gemert, J. P., Ravensbergen, S. J., Verschuuren, E. A. M., Kerstjens, H. A. M., Willemse, B. W. M., van Ingen, J., Hoefsloot, W., Gan, C. T., & Akkerman, O. W. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100800 · Cited by 9
Self-citationCatelli, C., Faccioli, E., Silvestrin, S., Lorenzoni, G., Luzzi, L., Bennett, D., Schiavon, M., Campisi, A., Bargagli, E., Dell’Amore, A., et al. (2024) · Cancers · doi:10.3390/cancers16030538 · Cited by 8
“For transplantation listing, a disease-free interval of five years is currently accepted for the majority of patients with a previous malignant condition [10].”
BackgroundImmune aging: biological mechanisms, clinical symptoms, and management in lung transplant recipients
Kapse, B., Budev, M. M., Singer, J. P., & Greenland, J. R. (2024) · Frontiers in Transplantation · doi:10.3389/frtra.2024.1356948 · Cited by 8
Lo, W., Muftah, M., Goldberg, H. J., Sharma, N., & Chan, W. W. (2024) · Diseases of the Esophagus · doi:10.1093/dote/doae020 · Cited by 9
Yeoh, H., Shingles, H. V., Paul, E. M., Levvey, B. J., Schwarz, M. A., Voskoboynik, M., Haydon, A. M., Shackleton, M. J., Snell, G. I., & Andrews, M. C. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100094 · Cited by 9
“35 However, risk stratification and prognostication for NMSC recurrence in the transplant population are required.”
ECMO for bridging lung transplantation
Zhang, C., Wang, Q., & Lu, A. (2024) · European journal of medical research · doi:10.1186/s40001-024-02239-y · Cited by 8
Appiani, F., Abara, B., Ramirez, I., et al. (2025) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.11.034 · Cited by 8
Liu, X., Chen, W., Du, W., Li, P., & Wang, X. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1583490 · Cited by 11
Kristobak, B. M., Bezinover, D. S., Geyer, N. R., & Cios, T. J. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.08.015 · Cited by 8
Antifibrotics and lung transplantation: A Spanish multicentre case‐controlled study
Cuesta, V. M. M., Fernandez, D. I., Ibáñez, S. A., Anguera, G., Iribarnegaray, J. M., Hernández-Rubio, J. C., Mezquida, J. P. R., Pérez-González, V. L., Hernández, R. L., Gafas, A. D. P., et al. (2022) · Respirology · doi:10.1111/resp.14352 · Cited by 9
“Therefore, lung transplantation should be considered among the therapeutic options for IPF since it is the only treatment for advanced stages of this disease that provides significant functional improvement and increased patient survival.(12,13) In fact, according to registry data from the International Society of Hea…”
BackgroundSelf-citationBoscolo, A., Dell’Amore, A., Pettenuzzo, T., Sella, N., CASSAI, A. D., Pistollato, E., Cacco, N., Manzan, A., Carolis, A. D., Geraldini, F., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195859 · Cited by 8
“Perioperative blood units **, n 2 [1, 3] 4 [2, 6] 8 [4, 14] 1.”
MethodWith Comparable Outcomes, Should Early-Stage Lung Cancer Be a Contraindication to Lung Transplant?
Spies, C. S., Ochoa, T. N., Pontula, A., Harris, C. S., Snyder, L. D., Pavlisko, E. N., & Hartwig, M. G. (2023) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2023.09.002 · Cited by 8
Self-citationSpece, L. J., Wai, T. H., Donovan, L. M., Duan, K. I., Plumley, R., Crothers, K. A., Thakur, N., Baugh, A. D., Hayes, S., Picazo, F., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1020oc · Cited by 8
Daar, J. A., Toyoda, Y., Shigemura, N., Baskin, S. M., Desai, P., & Gordon, M. (2024) · Respiratory Research · doi:10.1186/s12931-024-02968-y · Cited by 9
“This high-volume, single-center study represents one of the oldest cohorts of patients bridged to lung transplant on ECMO described, many of whom would be considered too high-risk by other transplant centers [20].”
BackgroundRamos, K. J., Wai, T. H., Stephenson, A. L., Sykes, J. R., Stanojevic, S., Rodriguez, P. J., Bansal, A., Mayer-Hamblett, N., Goss, C. H., & Kapnadak, S. G. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.05.021 · Cited by 9
Self-citationJennerich, A. L., Downey, L., Goss, C. H., Kapnadak, S. G., Pryor, J. B., & Ramos, K. J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02398-4 · Cited by 9
“Selecting optimal candidates for lung transplantation includes evaluating risk factors for adverse post-transplant outcomes [6], but this assessment can be imprecise, particularly related to pre-transplant malnutrition, which is known to be common among people with advanced CF lung disease.”
BackgroundSelf-citationThe Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient
Serrao, G. W., Vinayak, M., Nicolas, J., Subramaniam, V., Lai, A. C., Laskey, D. H., Kini, A. S., Seethamraju, H., & Scheinin, S. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247644 · Cited by 8
“…significant CAD that cannot be treated with revascularization, constitutes an important but not definitive disqualifier for undergoing a transplant [12] . layer of medical short and long prognosticator, myocardial long term, Despite that, data recipients are decade indicate have received increased…”
BackgroundInfluentialAl-Jahdali, H. H., Al-Lehebi, R. O., Lababidi, H. M., Alhejaili, F. F., Habis, Y., Alsowayan, W. A., Idrees, M. M., Zeitouni, M. O., Al-Shimemeri, A. A., Ghobain, M. A., et al. (2024) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_155_24 · Cited by 8
Bloem, A. E. M., Dolk, H. M., Wind, A. E., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107862 · Cited by 7
Novel Therapies for Right Ventricular Failure
Das, B. B. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02157-9 · Cited by 8
Melo-Narváez, M. C., Gölitz, F., Jain, E., Gote-Schniering, J., Stoleriu, M. G., Bertrams, W., Schmeck, B., Yildirim, A. Ö., Rauen, U., Wille, T., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03132-w · Cited by 8
Chronic lung diseases and kidney disease: pathophysiology and management
Rosa, S. D., Lassola, S., Taccone, F. S., & Battaglini, D. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf077 · Cited by 9
“Although data are limited, recent reports suggest that outcomes for selected patients undergoing combined transplantation can be comparable to those of isolated lung recipients, provided that a rigorous multidisciplinary assessment is performed before listing [112 ].”
InfluentialLung Transplantation in the Elderly: Is Age a Contraindication?
Shacker, M., Keogan, A. G., Wang, L., Roy, S. B., Arjuna, A., Walia, R., Hashimi, S., Bremner, R. M., Schaheen, L. W., Huang, J. L., et al. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.05.043 · Cited by 8
Yue, D., & Hu, Q. (2025) · BMC Public Health · doi:10.1186/s12889-025-22601-x · Cited by 8
“Recently, several guidelines emphasized the importance of frailty in the current clinical respiratory care as the prevalence and incidence of chronic lung disease (CLD) also increased with age [8–11].”
Caring for patients with advanced COPD: beyond the inhalers…
Murray, M., Mulryan, K., Chléirigh, M. N., Redmond, K., & Kelly, E. M. (2023) · Breathe · doi:10.1183/20734735.0229-2022 · Cited by 7
dos Anjos, L. R. B., Costa, V. A. F., Neves, B. J., Junqueira‐Kipnis, A. P., & Kipnis, A. (2023) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-023-03718-w · Cited by 7
Roles and practice of living-related lobar lung transplantation
Nakajima, D., & Date, H. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1867 · Cited by 7
“The increased severity of the LDLLT recipient illness, including severe malnutrition, long-term steroid use, hospitalization at the time of transplantation, and bridge to transplantation with the use of a ventilator or ECMO, have been listed as risk factors for post-transplant mortality according to the registry and c…”
MethodNutrition support management of organ transplant recipients in the acute posttransplant phase
Hahn, M., Wood, A., & Hasse, J. M. (2023) · Nutrition in Clinical Practice · doi:10.1002/ncp.11104 · Cited by 7
Update on Lung Transplantation for Cystic Fibrosis
Pilewski, J. M. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.07.002 · Cited by 8
2022 Update of indications and contraindications for lung transplantation in France
Pavec, J. L., Pison, C. M., Hirschi, S., Bunel, V., Mordant, P., Brugière, O., Guen, M. L., Olland, A., Coiffard, B., Renaud-Picard, B., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100981 · Cited by 7
Lung Transplantation: A Viable Option for Connective Tissue Disease?
Zhang, N., Liu, S., Zhang, Z., Liu, Y., Mi, L., & Xu, K. (2023) · Arthritis Care & Research · doi:10.1002/acr.25133 · Cited by 9
“The International Society for Heart & Lung Transplant (ISHLT) consensus on lung transplantation in patients with CTD has not changed the recommendation for referral and listing of patients who received treatment with new anti fi brotic drugs (6).”
BackgroundBermudez, J., Nathan, N., Coiffard, B., Roux, A., Hirschi, S., Dégot, T., Bunel, V., Pavec, J. L., Macey, J., Borgne, A. L., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00240-2023 · Cited by 8
“GDS, and especially SFTPA1 and SFTPA2 mutations, may be associated with lung cancer [25, 26] which is a classical contraindication to LTx within 5 years after cancer treatment [27].”
BackgroundOutcomes of lung transplantation in cystic fibrosis
Avdimiretz, N., Halloran, K. M., & Benden, C. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001108 · Cited by 7
Effect of revised organ transplant law in Japan on lung transplantation
Imamura, Y., Nakajima, D., Kanou, T., Shintani, Y., Sugimoto, S., Toyooka, S., Hoshikawa, Y., Matsumoto, K., Nagayasu, T., Suzuki, H., et al. (2024) · Surgery Today · doi:10.1007/s00595-024-02839-5 · Cited by 6
“Therefore, the ISHLT guidelines recommended the early referral of IP patients to a transplant facility [16].”
Lee, S. Y., Ahn, J. H., Kim, H., Shim, T. S., Kang, P. J., Lee, G. D., Choi, S., Jung, S., Park, S.-I., & Hong, S. (2024) · Transplant International · doi:10.3389/ti.2024.12657 · Cited by 6
“The 2021 guidelines from the International Society for Heart and Lung Transplant recommend listing patients for lung transplantation when they show signs of pulmonary hypertension or RV failure, as these conditions are associated with poorer outcomes [4].”
MethodWhat Happens to Frailty in the First Year After Lung Transplantation?
Fuller, L., Whitford, H. M., Robinson, R., Cristiano, Y., Steward, R., Poulsen, M., Paul, E. M., & Snell, G. I. (2024) · Clinical Transplantation · doi:10.1111/ctr.15393 · Cited by 7
“There are no guidelines on the format, timing or content of post-LTx programs, despite being recommended [3].”
Wu, K. A., Kim, J. K., Rosser, M. A., Chow, B., Bottiger, B., & Klapper, J. A. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-02952-z · Cited by 6
“The decision to transplant a patient entails consideration of many factors, including the severity of lung disease, efficacy of alternative treatments, the patient’s general health status, and likelihood of success [4].”
BackgroundPulmonary hypertension associated with COPD: a phenotype analysis
Steger, M., Canuet, M., Martin, G., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00716-2024 · Cited by 6
“Unfortunately, lung transplantation is often contraindicated in COPD patients with PVP due to age and comorbidities [29].”
The use of mechanical ventilation in interstitial lung disease
Nolan, T., Dwyer, I., & Geoghegan, P. (2025) · Breathe · doi:10.1183/20734735.0172-2024 · Cited by 9
Lung transplantation for interstitial lung disease
Ronan, N. J., Helly, F., & Murray, M. (2025) · Breathe · doi:10.1183/20734735.0169-2024 · Cited by 8
“Important ethical considerations in lung transplantation include utility (maximising the benefit from the scare resource that is suitable lungs for transplant), justice (using medical urgency to allocate organs) and respect for persons [3].”
InfluentialInterstitial Lung Disease: A Focused Review for the Emergency Clinician
Constantino, K., Gottlieb, M. A., & Long, B. (2023) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2022.10.015 · Cited by 8
Gramegna, A., Misuraca, S., Lombardi, A., Premuda, C., Barone, I., Ori, M., Amati, F., Retucci, M., Nazzari, E., Alicandro, G., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02612-1 · Cited by 7
“Moreover, it poses a relative contraindication for lung transplant due to the NTM’s inherent resistance to antimicrobial therapy [11– 14].”
BackgroundGlobal Leadership Initiative on Malnutrition-Diagnosed Malnutrition in Lung Transplant Candidates
Calañas-Continente, A., Gutiérrez-Botella, J., García-Currás, J., Cobos, M., Vaquero, J. M., Herrera-Martínez, A. D., Molina, M. J., & Gálvez, M. Á. (2024) · Nutrients · doi:10.3390/nu16030376 · Cited by 7
“Globally, LT should be considered in patients with a 50% higher risk of mortality at 2 years without transplantation and when the expected 5-year survival rate is greater than 80% considering normal graft function [3].”
BackgroundInfluentialIshii, S., Hatano, M., Minatsuki, S., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0790 · Cited by 6
The role of coronary artery disease in lung transplantation: a propensity-matched analysis
Lüsebrink, E., Gade, N., Seifert, P., Ceelen, F., Veit, T., Fohrer, F., Hoffmann, S., Höpler, J., Binzenhöfer, L., Roden, D., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02445-y · Cited by 6
“Patient selection was performed following interdisciplinary discussion in the transplantation conference and in accordance with contemporary ISHLT selection guidelines [15, 25].”
InfluentialEpidemiology of perioperative RV dysfunction: risk factors, incidence, and clinical implications
Shelley, B., McAreavey, R., & McCall, P. J. (2024) · Perioperative Medicine · doi:10.1186/s13741-024-00388-6 · Cited by 6
Nikkuni, E., Hirama, T., Ui, M., Watanabe, T., Mukai, S., Watanabe, T., Watanabe, Y., Oishi, H., Ebihara, S., & Okada, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03168-6 · Cited by 6
“The candidate selection consensus proposed by the International Society for Heart and Lung Trans-plantation highlights the presence of restrictive chest-wall or vertebral deformities as significant risk factors [25].”
BackgroundArunachalam, A., Anjum, F., Rosenheck, J. P., et al. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100155 · Cited by 6
“2,3 Therefore, the SLT cohort, with potentially inferior outcomes and an increased risk for serious adverse events resulting from invasive TBBx procedures, may be expected to benefit most from a noninvasive surveillance bio-marker solution.”
Survey of Extracorporeal Life Support Application in Lung Transplantation
Wilkey, B., Elliott, T. V., Jones, T. E., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70094 · Cited by 6
“This allows severely ill patients to remain candidates while avoiding the deleterious effects of long-term mechanical ventilation and sedation [4, 12-15].”
Bayomy, O. F., Ramos, K. J., Wai, T. H., Kapnadak, S. G., Morrell, E. D., Nomitch, J. T., Pollack, L. R., Lease, E. D., Aitken, M. L., Stephenson, A. L., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202202-110oc · Cited by 6
Self-citationRazia, D., Olson, M. T., Grief, K., Walia, R., Bremner, R. M., Smith, M. A., & Tokman, S. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.002 · Cited by 6
“Patients with CARDS were deemed appropriate for LT if they met the following criteria: (1) no evidence of pulmonary recovery despite SARS-CoV-2 clearance, (2) inability to wean from highflow supplemental oxygen, mechanical ventilation, and/or ECMO for at least 2 months after the onset of ARDS, (3) absence of irreversi…”
State of the art – Extracorporeal membrane oxygenation as a bridge to thoracic transplantation
Orozco‐Hernandez, E. J., DeLay, T. K., Góngora, E., Bellot, C. S., Rusanov, V., Wille, K. M., Tallaj, J. A., Pamboukian, S. V., Kaleekal, T. S., McElwee, S., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14875 · Cited by 6
Rudym, D., Natalini, J. G., & Trindade, A. J. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.002 · Cited by 6
Extracorporeal Membrane Oxygenation: Set-up, Indications, and Complications
Niroomand, A., Olm, F., & Lindstedt, S. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-26625-6_15 · Cited by 6
Tomioka, Y., Tanaka, S., Otani, S., Shiotani, T., Yamamoto, H., Miyoshi, K., Okazaki, M., Sugimoto, S., Yamane, M., & Toyooka, S. (2023) · Surgery Today · doi:10.1007/s00595-023-02699-5 · Cited by 6
Transplanting candidates with stacked risks negatively affects outcomes
Cantu, E., Dun, J., McCurry, M., Friskey, J., Lisowski, J., Saleh, A., Diamond, J. M., Anderson, M. R., Clausen, E. S., Hsu, J. Y., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.05.020 · Cited by 6
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
